Skip to main content
IMUX logo

IMUX · Immunic, Inc. · Investor Relations

Track IMUX — free
$8.02 +0.41 (+5.39%) Q3 2024 earnings call transcript
Market Cap
$103.83M
Shares
13.64M
Volume · Oct 28 89.32K Avg daily vol (3M) 327.56K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-10-21 MSToronto2026 – 10th Joint ACTRIMS-ECTRIMS Meeting Event
2026-10-19 TOPRA Symposium 2026 Event
2026-09-23 2026 Leerink Partners Biopharma Summit Event
2026-09-16 J.P. Morgan - The Munich LifeScience Forum 2026 Event
2026-09-13 EUROTOX 2026 Event
2026-09-09 Immunic's Virtual Relapsing MS R&D Day Event
2026-09-06 EFMC Medicinal Chemistry 2026 Basel Event
2026-08-11 Second Quarter 2026 Financial Results and Corporate Update Results publication
2026-08-07 2026 AAN Autoimmune Neurology Conference Conference
2026-08-06 Second Quarter 2026 Financial Results and Corporate Update Results publication
2026-07-31 TNS 2026 Summer Conference Conference
2026-07-23 LifeSci Capital SF Biotech Forum Event
2026-07-16 B. Riley Securities Mind, Muscle & Vision Summit Event
2026-07-14 Leerink Partners Therapeutics Forum Event
2026-06-27 12th Congress of the European Academy of Neurology (EAN) Event
2026-06-22 EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026 Symposium Event
2026-06-22 BIO International Convention 2026 Event
2026-05-27 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting Shareholder meeting
2026-05-13 First Quarter 2026 Financial Results and Corporate Update Results publication
2026-05-12 IQPC Clinical Trial Supply Forum Event
2026-05-12 26th Bio€quity Europe Event
2026-05-06 RAPS Euro Convergence 2026 Event
2026-05-06 16th Annual Outsourcing in Clinical Trials Europe 2026 Event
2026-05-05 61st European Medical Writers Association (EMWA) Spring Conference 2026 Conference
2026-05-04 26th Bio€quity Europe Event

Source: https://ir.imux.com/

Key facts CIK 1280776 CUSIP 4525EP200 13F (30d) 3 filings 3 filers Visit website Investor relations